AFP and hepatocellular carcinoma: In the present study, we determined the prognostic performances of hPG80 in clinically diagnosed HCC patients, alone or in combination with AFP, and examined whether hPG80 might improve the stratification of patients to predict overall survival (OS), taking into account the BCLC staging or not.